Trial Parameters
Brief Summary
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.
Eligibility Criteria
N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, non-exercising subtype Inclusion criteria: * Age 18-60 years * Written informed consent * BMI 10-16 kg/m2 N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study. Inclusion criteria: * Age 18-60 years * Written informed consent * BMI 10-16 kg/m2 N=16 control participants, sex- and age-matched to the individual anorexia nervosa patients. Inclusion criteria: * Age 18-60 years * Written informed consent * BMI 19-24.9 kg/m2 Exclusion Criteria: * Use of antibiotics within the last 31 days * Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed) * Any kind of severe chronic disease other than AN (e.g. active cancer disease) * Severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2) if resulting from another diseas